Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 10/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4647285 | 0.77 | GAA (0.60) | ALDH1A1GAAL3MBTL1NPC1TSHR | |
| SCHEMBL4648732 | 0.75 | GAA (0.78) | ALDH1A1GAAL3MBTL1NPC1HSD17B10 | |
| SCHEMBL19732942 | 0.73 | POLB (0.70) | ALDH1A1GAAL3MBTL1MAPK1POLB | |
| SCHEMBL19732943 | 0.73 | POLB (0.70) | ALDH1A1GAAL3MBTL1MAPK1POLB | |
| SCHEMBL13745523 | 0.73 | GAA (0.76) | GAAL3MBTL1NPC1HSD17B10TSHR | |
| SCHEMBL2572171 | 0.73 | MAPK1 (0.55) | ALDH1A1GAAMAPK1HSD17B10POLB | |
| SCHEMBL4646686 | 0.72 | GAA (0.55) | ALDH1A1GAAL3MBTL1NPC1TSHR | |
| SCHEMBL14413865 | 0.71 | GAA (0.56) | ALDH1A1GAAL3MBTL1HSD17B10POLB | |
| SCHEMBL6348122 | 0.71 | HTT (0.75) | ALDH1A1MAPK1HSD17B10POLBHTT | |
| SCHEMBL19732926 | 0.70 | ALDH1A1 (0.80) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771331-B2 | Methods of identifying neuroprotective compounds for retinal ganglion cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215765-A1 | Neuroprotective compounds for treating optic neuropathies | NLN, GAP43, AIFM1 | ALDH1A1 1691/4885GAA 3458/4885L3MBTL1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.